196 related articles for article (PubMed ID: 11598362)
1. Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy.
Uszyński M; Maciejewski K; Uszyński W; Kuczyński J
Gynecol Obstet Invest; 2001; 52(3):189-93. PubMed ID: 11598362
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
3. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
4. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.
Moniwa N
Pol J Pharmacol; 1996; 48(2):215-20. PubMed ID: 9112654
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
Uszyński M; Perlik M; Uszyński W; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
[TBL] [Abstract][Full Text] [Related]
6. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Montemurro P; Conese M; Altomare DF; Memeo V; Colucci M; Semeraro N
Int J Clin Lab Res; 1995; 25(4):195-200. PubMed ID: 8788547
[TBL] [Abstract][Full Text] [Related]
7. Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid.
Kinnby B; Matsson L; Astedt B
J Periodontal Res; 1996 May; 31(4):271-7. PubMed ID: 8814598
[TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women.
Uszyński M; Uszyński W; Zekanowska E; Garbacz J; Kielkowski A; Marcinkowski Z
J Perinat Med; 1996; 24(4):339-45. PubMed ID: 8880631
[TBL] [Abstract][Full Text] [Related]
9. [Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks].
Uszyński W; Uszyński M
Ginekol Pol; 2004 Dec; 75(12):971-8. PubMed ID: 15751221
[TBL] [Abstract][Full Text] [Related]
10. The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis.
Reddick KL; Smrtka MP; Grotegut CA; James AH; Brancazio LR; Swamy GK
Am J Perinatol; 2014 Oct; 31(9):735-40. PubMed ID: 24338119
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
15. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator and plasminogen activator inhibitors of types 1 and 2 in amniotic fluid before labour and after childbirth.
Uszyński M; Uszyński W; Kiełkowski A
Gynecol Obstet Invest; 1995; 39(2):93-6. PubMed ID: 7737590
[TBL] [Abstract][Full Text] [Related]
17. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
18. Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid.
Verkleij-Hagoort AC; Ursem NT; Hop WC; Geurts-Moespot A; Steegers EA; Sweep FC; Steegers-Theunissen RP
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):47-52. PubMed ID: 17141398
[TBL] [Abstract][Full Text] [Related]
19. The effect of cyclosporine on regulators of fibrinolysis in plasma from renal allograft recipients.
Elhasade AS; Perkowska A; Paczek L; Rowiński W; Soluch L; Szmidt J; Gałazka Z; Gaciong Z
Ann Transplant; 1998; 3(1):13-8. PubMed ID: 9869892
[TBL] [Abstract][Full Text] [Related]
20. The relationship between urokinase plasminogen activator/plasminogen activator inhibitor type-1 expression in myoma/myometrium and mechanism of uterine artery occlusion by laparoscopy for uterine myoma treatment.
Zhu Y; Cheng Zp; Dai H; Hu Lp
Blood Coagul Fibrinolysis; 2009 Oct; 20(7):565-70. PubMed ID: 19593113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
